Diuretic compositions

ABSTRACT

5-ARYLSULFAMYL-4-HALO-ANTHRANILIC ACIDS, E.G. THOSE OF THE FORMULA   1-(HOOC-),2-(R1-N(-R2)-),4-R3,5-(PHENYL-HN-O2S-)BENZENE   R1=ALIPHATIC OR ARALIPHATIC RADICAL R2=H OR R1 R3=C1 OR BR AND FUNCTIONAL DERIVATIVES THEREOF, EXHIBIT DIURETIC EFFECTS.

United States Patent 3,658,990 DIURETIC COMPOSITIONS Lincoln Harvey Werner, Summit, N.J., assiguor t0 Ciba-Geigy Corporation, Ardsley, N.Y.

N0 Drawing. Continuation-in-part of application Ser. No. 675,330, Oct. 16, 1967, which is a continuation-in-part of application Ser. No. 598,980, Dec. 5, 1966. This application June 10, 1969, Ser. No. 832,029

Int. Cl. A61k 27/00 US. Cl. 424-228 3 Claims ABSTRACT OF THE DISCLOSURE -arylsulfamyl-4-halo-anthranilic acids, e.g. those of the formula mro s coon l l I I R R N/ l R =aliphatic or araliphatic radical and functional derivatives thereof, exhibit diuretic efiects.

CROSS-REFERENCES TO RELATED APPLICATIONS This is a continuation-impart of application Ser. No. 675,330, filed Oct. 16, 1967, which in turn is a continuation-in-part of application Ser. 'No. 598,980, filed Dec. 5, 1966, both are now abandoned.

SUMMARY OF THE INVENTION The present invention concerns and has for its object the provision of new 5-arylsulfamyl-4-halo-anthranilic acids and their therapeutically acceptable derivatives, more particularly those of Formula I,

COOl-l in which each of R R and R stands for an aliphatic or araliphatic radical, R and R also for hydrogen, R for chloro or bromo and R for a carbocyclic or heterocyclic aryl radical, esters, amides, acyl derivatives and/ or salts thereof, as well as of corresponding pharmaceutical compositions, new starting materials and methods for the preparation and application of these products. Said compositions are primarily useful as orally applicable diuretic, natriand chloriuretic agents in order to relieve excessive water and/or salt retention, for example, in connection with heart and kidney diseases, and in the adjunctive management of hypertension.

DESCRIPTION OF THE PREFERRED EMBODIMENTS The aliphatic or araliphatic radicals mentioned for R R and R are hydrocarbon radicals, which may be substituted by functional groups and/ or interrupted by heteroatoms, such as nitrogen, oxygen and/ or sulfur atoms. Such radicals are, for example, lower alkyl, e.g. methyl, ethyl, nor i-propyl, n-, i-, or sec. butyl, nor ipentyl, neopentyl, n-hexyl or n-heptyl, lower alkenyl, e.g. vinyl, allyl, methallyl or Z-butenyl, lower alkynyl, e.g. propargyl, monoor bicyclic cycloalkyl, cycloalkenyl, cycloalkyl-lower alkyl or cycloalkenyl-lower alkyl with preferably 5 to 7 ring-carbon atoms, 1 to 4 chain carbon atoms and optional, e.g,. up to 4, lower alkyl groups, e.g. cyclopropyl, 2,3-dimethyl-cyclopropyl, cyclobutyl, cyclopentyl, 2- or 3-methyl-cyclopentyl, 2,5- or 3,4-dimethylcyclopentyl, cyclohexyl, 2-, 3- or 4-rnethyl-cyclohexyl, 2-, 3-, 2,4- or 3,5-dimethyl-cyclohexyl, 2,4,6-trimethyl-cyclohexyl, cycloheptyl, cyclooctyl, 2- or 7-norbornanyl, 1- or Z-decahydronaphthyl; 1- or 2-cyclopentenyl, 2,4-cyclopentadienyl, 2- or 3-methyl-2-cyclopenteny1, 4,5-dirnethyl- 2-cyclopentenyl, l-, 2- or 3-cyclohexenyl, 2,5-cyclohexadienyl, 2-, 3- or 4-methyl-1- or Z-cyclohexenyl, 2,4- or 3,5- dimethyl-lor 2-cyclohexenyl, 2,4,6-trimethyl-2,5-cyclohexadieny-l, 1-, 2- or 3-cycloheptenyl, 2,6-cycloheptadienyl, 2-cyclooctenyl or 2-norborn-5-enyl, as well as the corresponding cycloalkylor cycloalkenyl-lower alkyl groups in which the chain especially represents methyl, but also ethyl nor i-propyl, n-, ior sec. butyl; it contains in any of the positions available for substitution one of the specific cycloalkyl or cycloalkenyl groups listed above. The term lower, referred to above and hereinafter in connection with organic radicals or compounds respectively, defines such with up to 7, preferably up to 4, carbon atoms. Aliphatic radicals that are substituted, e.g. by free or functionally converted hydroxy, mercapto or carboxy groups and/or interrupted by heteroatoms, e.g. one oxygen, sulfur and/ or nitrogen atom, are represented, for example, by lower haloalkyl, e.g. 2-(chloro, bromo or iodo)-ethyl, 3,3-difluoroor -dichloropropyl, 3,3,3-trichloropropyl, 3- or 4-chlorobutyl, 4,4- or 3,4-dichlorobutyl or 4,4,4-trifluorobutyl; unsubstituted or halogenated lower alkoxyor alkylmercapto-lower alkyl, such as 2- ethoxyethyl, 3-methoxy-propyl, Z-ethylrnercapto-ethyl, 2- (2,2-dichloroethoxy)-ethyl, 2-(2-chloroethoxy)-ethyl, 2- (2,2,2-trifluoroethylmercapto)-ethy1 or 2-(2,2-dichloroethylmercapto)-ethyl; carbamyl-lower alkyl or N,N-dilower alkylcarbamyl-lower alkyl, such as carbamylmethyl, N,N-dimethylcarbamyl-methyl, Z-carbamyl-ethyl or 2-N,N-diethylcarbamyl-ethyl; sec. or tert. amino-lower alkyl, such as monoor di-lower alkylamino-lower alkyl, lower alkyleneimino-lower alkyl, lower monoaza-, -oxaor -thiaalkyleneimino-lower alkyl or N-lower alkyl-lower monoazaalkyleneimino-lower alkyl, e.g. 2-ethy1aminoethyl, Z-dirnethylamino-ethyl, 3-diethylamino-propyl, 2- pyrrolidino ethyl, 2 piperidino ethyl, 2 (4 methylpiperazino) ethyl or 2 morpholino ethyl, 5 to 7 ring membered oxa-cycloalkyl or -cycloalkenyl, oxacycloalkylor -cycloalkenyl-lower alkyl, such as 3-tetrahydrofuryl, tetrahydrofuryl-Z-methyl, (2 methyl-tetrahydrofuryl-2) methyl, 2,3-dihydroor tetrahydropyranyl-Z-methyl.

R and R when taken together, may also represent lower alkylene or alkenylene, e.g. 1,2-ethylene, 1,3- propylene, 1,4-butylene, 1,4- or 1,5-pentyler1e, 1,5-, 2,5- or 1,6-hexylene or 2,6-heptylene; 1,4-but-2-enylene 1,4- or 1,5-pent-2-enylene, 1,5-hex-2-enylene, 1,6-hex-3-enylene or 2,6-hept-3-enylene; lower monoaza-, -oxaor -thiaalkylene or N-lower alkyl-monoaza-lower alkylene, e.-g. 3-aza-, 3-oxaor 3-thia-pentylene-(1,5), 3-methylor 3-ethy-l-3-aza-pentylene-(1,5), 3-aza-hexylene-(1,6) or 4- azaor oxa-heptylene-(2,6). In the aliphatically s'ubstituted group two heteroatoms, e.g. nitrogen, oxygen and/or sulfur atoms, are separated by at least 2 carbon atoms.

An araliphatic radical R R and R preferably stands for monoor bicyclic carbocyclic aryl-lower alkyl or aryl-lower alkenyl, especially (monoor di-R -phenyl)- lower alkyl or -alkenyl, but also for monoor bicyclic heterocyclic, especially monoaza-, oxaor thiacyclic aryllower alkyl or aryl-lower alkenyl in which the alkyl or alkenyl moiety preferably has up to 4 chain carbon atoms, and the aromatic portion is unsubstituted or substituted by one or more than one, preferably 1 or 2, substituents selected, for example, from lower alkyl, e.g. that mentioned above, phenyl, free or functionally converted bydroxy or mercapto, such as lower alkoxy, lower alkylenedioxy, lower alkylmercapto or halogeno, e.g. methoxy, ethoxy, nor i-propoxy or -butoxy, methylenedioxy, 1,1- or 1,2-ethylenedioxy, methylor ethylmercapto, fluoro, chloro or bromo; (hydroxy or halogeno)-lower alkyl or -alkoxy, e.g. Z-hydroxyethyl, trifluoromethyl or 2-hydroxyethoxy, nitro, amino, especially di-lower alkylamino, e.g. dimethylamino or diethylamino, sulfamoyl, or free or functionally converted carboxy, e.g. lower carbalkoxy, carbamoyl or cyano. Preferred aryl-substituents R are hydrogen, lower alkyl, hydroXy-lower alkyl, hydroxy, mercapto, lower alkoxy, lower alkylmercapto, hydroXylower alkoxy, halogeno, trifluoromethyl, nitro, amino, dilower alkylamino, carboxy and/or lower car-balkoxy. Unsubstituted carbocyclic aralkyl or aralkenyl radicals are exemplified by benzyl, 1- or Z-phenylethyl, 1-, 2- or 3- phenyl-propyl, 2 phenyl 2 propyl, 1-, 2-, 3- or 4- phenyl-butyl, lor 2 phenyl 2 butyl, styryl or cinnamyl. In the corresponding heterocyclic aralkyl or aralkenyl radicals aryl is preferably monocyclic monoaza-, -oxaor -thiacyclic aryl, e.g. 2-, 3- or 4-pyridyl, 2- or 3-furyl or -thienyl, but also 5-(1,2-oxazolyl), 2-(l,3- oxazolyl), 2-( 1,3 -thiazolyl), 6-thianaphthyl or Z-benzimidazolyl. Araliphatic radicals are also partially hydrogenated, preferably bior tricyclic aryl radicals, bound at the aliphatic portion, such as 1- or Z-indolinyl, 1- or 2-(l,2,3,4-tetrahydronaphthyl) or 9-fluorenyl.

The radical R preferably stands for monoor bicyclic carbocyclic or heterocyclic aryl, e.g. that mentioned for the above araliphatic radicals. It especially represents monoor di-R -phenyl, in which R has the meaning given above.

Esters and amides of the compounds of Formula I are particularly lower alkyl esters, the amide, monoor diloweralkylamides, (hydroxy or lower alkoxy)-lower alkyl esters or amides, (amino, monoor di-lower alkylamino)- lower alkyl esters or amides, wherein two heteroatoms are separated by at least 2, preferably 2 or 3, carbon atoms, e.g. the methyl, ethyl, nor i-propyl or -b-utyl ester, the amide, monoor dimethylamide, diethylamide or i-propylamide, the 2-(hydroxy or methoxy) -ethyl ester or amide, Z-(amino, monoor dimethylamino)-ethyl ester or amide or 3-dimethylamino-propyl ester or amide, or aralkyl esters, such as (.R -phenyl)-lower alkyl, e.g. benzyl, 1- or Z-phenethyl esters.

The acyl derivatives are preferably those of lower alka noic acids, such as acetic, propionic, butyric or pivalic acid, but also of lower alkenoic acids, such as acrylic or methacrylic acid, or of R -phenyl-lower alkanoic or -alkenoic acids, such as benzoic, phenylacetic or cinnamic acid. The acyl group therein is preferably attached to a primary, but also a secondary amino group and/or a free hydroxy or mercapto group.

The compounds of the invention exhibit valuable pharmacological properties. Primarily they show diuretic, natriand chloriuretic activity with rapid onset of action, high urine but low potassium excretion levels. This can be demonstrated in animal tests using, for example mammals, e.g. rats or dogs, as test objects. Such tests can be performed, for example, by administering the compounds of the invention within a gelatin capsule to dogs, or in the form of aqueous solutions or suspensions by stomach tube to rats, in an oral dosage range between about 0.1 and 100 mg./kg./day, preferably between about 0.3 and 50 mg./kg./day, advantageously between about 1 and 5 mg./kg./day. Simultaneously the test animals may receive various salt loads enterally or parenterally, for example, various amounts of subcutaneously applied 0.9% saline, e.g. 100 ml. thereof per medium-sized dog (beagle). Urin is then collected, e.g. at 2 hour intervals,

with or without catheterization, and its volume, sodium, potassium and chloride content estimated and compared with that of the same untreated or saline-treated animals. Besides the above-mentioned utility, the compounds of the invention can also be used as itnermediates in the preparation of other valuable products, primarily of pharmacologically active compounds.

Preferred are those compounds of Formula I in which R is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, cycloalkyl-alkyl, cycloalkenyl-alkyl, oXa-cycloalkyl or -cycloalkenyl, oxa-cycoalkylor -cycloalkenyl-lower alkyl, with 5 to 7 ring-carbon and l to 4 chain carbon atoms, lower fluoroor chloroalkyl, lower alkoxyor alkylmercapto-lower alkyl, lower fluoroor chloroalkoxyor -alkylmercapto-lower alkyl, (ii-lower alkylaminoor loweralkyleneimino-lower alkyl, R and R are hydrogen, lower alkyl or (monoor di-R -phenyl)-alkyl with 1 to 4 chain carbon atoms, R is chloro and R is monoor diR phenyl or unsubstituted or lower alkyl-substituted monocyclic monoaza-, -oxaor -thiacyclic aryl, preferably pyridyl, furyl or thienyl, or especially those compounds of Formula I, in which R -R have the meaning given in this paragraph and R is (monoor di-R -phenyl)-alkyl or unsubstituted or lower alkyl-substituted monocyclic monoaza-, -oxaor -thiacyclic arylalkyl with l to 4 chain carbon atoms, or lower alkanoyl derivatives of compounds containing a primary or secondary amino group, or lower alkyl esters, the amide, monoor di-lower-alkylamides, (hydroxy or lower alkoxy)-lower alkyl esters or amides, (amino, monoor di-lower alkylamino)-lower alkyl esters or amides, wherein two heteroatoms are separated by at least 2 carbon atoms, the alkali metal, alkaline earth metal or ammonium salts of said anthranilic acids, or acid addition salts of basic compounds.

Especially valuable are the compounds of Formula II R -l|l0 S COOH in which each of R7 and R is phenyl, monoor dilower alkylphenyl, lower hydroxyalkylphenyl, monoor dihydroxyphenyl, lower alkylhydroxyphenyl, monoor di-mercaptophenyl, monoor di-lower alkoxyphenyl, lower alkoxy hydroxyphenyl, lower hydroxyalkoxyphenyl, monoor di-lower alkylmercaptophenyl, monoor dihalogenophenyl, trifluoromethylphenyl, nitrophenyl, monoor diaminophenyl, di-lower alkylaminophenyl, lower alkanoylaminophenyl, carboxyphenyl, lower carbalkoxyphenyl, pyridyl, lower alkylpyridyl, furyl, lower alkylfuryl, thienyl, lower alkylthienyl, tetrahydrofuryl, lower alkyltetrahydrofuryl, dihydropyranyl or lower alkyldihydropyranyl, and each of R and R is hydrogen or lower alkanoyl, the lower alkyl esters, the amide, monoor di-loweralkylamides, (hydroxy or lower alkoxy)-lower alkyl esters or amides, (amino, monoor dilower alkylamino)-lower alkyl esters or amides, wherein two heteroatoms are separated by at least 2 carbon atoms, the alkali metal, alkaline earth metal, ammonium or acid addition salts thereof.

Outstanding are the compounds of Formula II, in which R7 is phenyl, Z-furyl, Z-thienyl, Z-tetrahydrofuryl, Z-methyl 2 tetrahydrofuryl or 2,3-dihydro 2 'pyranyl, each of R 2 and R is hydrogen or acetyl and R is phenyl, monoor dimethylphenyl, Z-hydroxyethylphenyl, monoor dihydroxyphenyl, methyl-hydroxyphenyl, mercaptophenyl, monoor dimethoxyphenyl, methoxy-hydroxyphenyl, 2 hydroxyethoxyphenyl, fiuorophenyl, chlorophenyl, trifluoromethylphenyl, nitrophenyl, monoor diaminophenyl, dimethylaminophenyl, acetyla-minophenyl, cauboxyphenyl, carbomethoxyphenyl or carbethoxyphenyl, the methyl or ethyl ester, 3-di=methylaminopropylamide, the sodium, potassium or 2 hydroxyethylammonium salts of the carboxylic acids or the hydrochlorides of the monoor diamino or dimethylamino compounds.

Most preferred are the N-furfuryl 5 phenylsulfamyl- 4-chloroanthranilic acid and the N-furfuryl- 5 (4- hydroxy, methoxyor amino pheuylsulfamyl)-4-chloroanthranilic acid and their sodium or Z-ethanolammonium carboxylic acid salts or the hydrochloride of the 4- aminophenyl compound which, when given to dogs at oral doses between about 1 and S mg./kg./day, exhibit high diuretic, natriand chloriuretic effects.

The compounds of the invention are prepared ac cording to methods in themselves known. Advantageously they are obtained by converting in a compound of the Formula III coon R 7No s R (III) in which X stands for a group capable of being converted I into the amino group an ester, halide, amide, hydrazide, acyl derivative or salt thereof, X into is preferably a halogen atom, advantageously flu-oro or chloro, but also primary amino or an imino group, forming after reduction (of the corresponding Schifis base) the group R NH. The starting material, in which X stands for halogeno, is reacted with the amine that in which X stands for -NH is reacted with a reactive ester of the alcohol R OH, e.g. such of a hydrohalic or sulfonic acid, e.g. hydrochloric, hydrobromic, hydriodic, methane-, ethane-, benzeneor p-toluenesulfonic acid, Whereas that starting material, in which X stands for said imino group, is subjected to hydrogenation, for example, with the use of catalytically activated or nascent hydrogen.

The above process is carried out according to standard methods, in the presence or absence of diluents, preferably such as are inert to the reagents and are solvents thereof, of catalysts, condensing agents and/or inert atmospheres, at low temperatures, room temperature or advantageously elevated temperatures, at atmospheric or superatmospheric pressure.

In the above reaction the amine reagent is advantageously used in excess, in order to neutralize any gen erated acid. It may, however, also be used in equivalent amounts and in the presence of other condensing agents such as inorganic or organic bases, e.g. alkali metal carbonates or bicarbonates or tertiary nitrogen bases, for example tri-lower alkylamines, N,N-dimethyl-aniline or pyridine.

Any resulting amide or hydrazide can be hydrolyzed in the usual manner, for example, with the use of a base, e.g. an aqueous alkali or alkaline earth metal hydroxide, or a quaternary ammonium hydroxide. The compounds of the invention so obtained may be converted into each other according to known methods. For example, resulting compounds in which R and/or R stands for hydrogen, may be reacted with a reactive ester of a corresponding alcohol, for example that of a hydrohalic or s-ulfonic acid. Resulting compounds with a hydroxy, prim. or sec. amino group may be acylated, for example, with a reactive functional derivative of a corresponding acid, such as a halide or anhydride thereof, e.g. thionyl or acetyl chloride or acetanhydride, resulting acyl derivatives or esters may be hydrolyzed, for example with the use of acidic or alkaline hydrolyzing agents, resulting esters may be transesterified or reacted with corresponding amines or resulting acids esterified or amidated in known manner.

The compounds of the invention are obtained in the free form or in the form of their salts, depending on the conditions under which the process is carried out, the salts are also included in the present invention. These are particularly derived from the free acids and therapeutically useful inorganic or organic bases, primarily the alkali metal, alkaline earth metal, e.g. sodium, potassium, magnesium or calcium salts, or ammonium salts derived from ammonia or amines, such as those' corresponding to the amino group e.g. mono-, dior tri-lower alkylamines, -cycloalkylamines, -cycloalkyllower alkylamines or -aralkylamines, mixed amines or tertiary nitrogen bases, such as pyridine, collidine or lutidine. Resulting compounds that contain basic groups, eg amino groups, may also form acid addition salts, preferably such of therapeutically useful acids, such as mineral acids, eg, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric or perchloric acid; aliphatic or aromatic carboxylic or sulfonic acids, e.g. formic, acetic, propionic, succinic, glycollic, lactic, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, pyroracemic, phenylacetic, benzoic, 4-arninobenzoic, anthranilic, 4-hydroxybenzoic, salicylic, 4-aminosalicylic, embonic, nicotinic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, ethylenesulfonic, halogen-benzenesulfonic, toluenesulfonic, naphthalenesulfonic and sulfanilic acid; methionine, tryptophane, lysine and arginine.

The invention further includes any variant of the present process in which an intermediate product obtainable at any stage of the process is used as starting material and any remaining steps are carried out, or the process is discontinued at any stage thereof, or in which the starting materials are formed under the reaction conditions, or in which the reaction components are used in the form of their salts. Mainly those starting materials should be used in the reactions of the invention that lead to the formation of those compounds indicated above as being especially valuable.

The starting material is new and, therefore, a further object of the present invention. It can be prepared according to known methods, for example, a corresponding 2,4- dihalo-benzoic acid is reacted with chlorosulfonic acid in order to yield the 2,4-dihalo 5 chlorosulfonyl-benzoic acid. The latter, or a functional derivative thereof, is then reacted with the amine R -NHR in order to obtain the compounds of Formula III in which X stands for halogeno, or functional derivatives thereof. The latter, eg the esters, halides, amides or hydrazides, may also be prepared from the acids of Formula III by conventional methods. The resulting 2,4-dihalo 5 sulfamyl benzoic acids may be reacted with ammonia in order to obtain the starting material in which X represents NH which further may be reacted with a corresponding aldehyde or ketone, in order to obtain the starting material in which X stands for an imino group. I

The pharmacologically active compounds of the invention are useful in the manufacture of pharmaceutical compositions containing an effective amount thereof in conjunction or admixture with excipients suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredients together with (a) diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine, (b) lubricants, e.g. silica, talcum, stear-ic acid, its magnesium or calcium salt and/or polyethyleneglycol, for tablets also -(c) binders, e.g. magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylccllulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, if desired, (d) disintegrants, e.g. starches, agar, alginic acid or its sodium salt, enzymes of the binders or effervescent mixtures and/or (e) adsorbents, color-ants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously fatty emulsions or suspenions. They may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. They may also contain other therapeutically valuable substances. Said pharmaceutical compositions are prepared according to conventional mixing, granulating or coating methods respectively and contain about 0.1 to 75%, preferably about 1 to 50% of the active ingredient.

The following examples illustrating the invention are not to be construed as being limitations thereon. Temperatures are given in degrees centigrade and all parts Whereever given are parts by weight.

EXAMPLE 1 The mixture of 2.4 g., 2,4-dichloro-S-phenylsulfamylbenzoic acid, 10 ml. 2-ethoxy-ethanol and 2.7 g. furfurylamine is refluxed for 4 hours under nitrogen. After cooling to room temperature it is poured into 50 m1. 2 N- hydrochloric acid. The supernatant liquid is decanted off and the residue dissolved in 50 ml. 2 N aqueous sodium hydroxide. The solution is extracted twice with diethyl ether and acidified with hydrochloric acid. The precipitate formed is filtered off and recrystallized from ethanol to yield the N-furfuryl-S-phenylsulfamyl-4-chloroanthranilic acid of the formula HNOZS 0003 (j U O melting at 2102l2 (dec.).

The starting material is prepared as follows: To 250 g. chlorosulfonic acid 50 g. 2,4-dichloro-benzoic acid are added portion-wise at room temperature while stirring. The solution obtained is heated to about 180 and stirred for 3 hours. After cooling to room temperature, it is poured onto ice, the mixture filtered, the residue Washed with water, and dissolved in 400 ml. ethyl acetate. The solution is dried, filtered, evaporated, and the residue triturated with hexane, to yield the 2,4-dichloro-5-chlorosulfonyl-benzoic acid.

The mixture of 5.8 g. thereof, 7.5 g. aniline and 50 ml. ethyl acetate is stirred for 4 hours at room temperature. It is then filtered and the residue Washed with ethyl acetate. The filtrate is evaporated in vacuo and the residue triturated with 2 N hydrochloric acid. The aqueous solution is decanted off and the precipitate dissolved in 100 ml. aqueous potassium carbonate. The solution is filtered to yield residue A. The filtrate is extracted with diethyl ether and the aqueous layer acidified with hydrochloric acid. The precipitate formed is filtered olf, washed with water and recrystallized from aqueous ethanol to yield the 2,4-dichloro-5-phenylsulfamylbenzoic acid melting at 211- 213. Residue A is also recrystallized from aqueous ethanol to yield the 2,4-dichloro-5-phenylsulfamylbenzoic acid phenylamide melting at 173-l75.

8 EXAMPLE 2 The mixture of 3.0 g. N-furfuryl-S-phenylsulfamyl-4- chloro-anthranilic acid phenylamide, 30 ml. 2 N-aqueous sodium hydroxide, 10 ml. water and 10 ml. Z-methoxyethanol is refluxed for 3 hours under nitrogen and allowed to stand at room temperature overnight. It is poured into 60 ml. 2 N-hydrochloric acid, the precipitate formed filtered off, washed with water and dissolved in 35 ml. 10% aqueous potassium carbonate. The solution is extracted with ethyl acetate, the aqueous layer separated and acidified with hydrochloric acid. The precipitate formed is filtered oif, recrystallized from aqueous ethanol to yield the N-furfuryl-S-phenylsulfamyl-4-chloro-anthranilic acid melting at 2l2214 with decomposition; it is identical with the compound obtained according to Example 1.

The starting material is prepared as follows: The mixture of 6.0 g. 2,4-dichloro-S-phenylsulfamyl-benzoic acid phenylamide, 5.6 g. furfurylarnine and 20 ml. Z-methoxyethanol is refluxed for 4 hours under nitrogen and allowed to stand overnight at room temperature. It is poured into ml. 2 N-hydrochloric acid, the precipitate formed filtered oil? and the residue dissolved in diethyl ether. The solution is washed with 0.5 N hydrochloric acid, with 10% aqueous potassium carbonate and water, dried, filtered and evaporated in vacuo, to yield the N-furfuryl5-phenylsulfamyl-4-chl0ro-anthranilic acid phenylamide melting at 114-1l7.

EXAMPLE 3 Substituting in Example 1 the furfurylamine by the equivalent amount of benzylamine and performing the reaction as shown therein, the N-benzyl-S-phenylsulfamyl- 4-chloroanthranilic acid of the formula is obtained, M.P. 226-228 (from aqueous ethanol).

EXAMPLE 4 The mixture of 3.1 g. 2,4-dichloro-5-(4-methyl-phenylsulfamyl)-benzoic acid, 3.4 g. furfurylamine and 10 ml. Z-methoxyethanol is refluxed for 4 hours under nitrogen. After cooling to room temperature, it is treated with 2 N- hydrochloric acid, the precipitate formed separated and dissolved in 2 N-aqueous sodium hydroxide. The solution is extracted with diethyl ether, the aqueous layer separated and acidified with hydrochloric acid. The precipitate formed is filtered off and recrystallized from aqueous ethanol to yield the N-furfuryl-4-chloro-5-(4-methylphenyl-sulfamyl)-anthranilic acid of the formula ginseng-o 0 on 1130 o1 NH-OH i i melting at 218-220".

The starting material is prepared as follows: To the solution of 5.8 g. 2,4-dichloro-5-chlorosulfonyl-benzoic acid in 50 ml. ethyl acetate, 8.6 g. p-toluidine are added while stirring, followed by 100 ml. ethyl acetate. The mixture is stirred at room temperature for 2 hours and refluxed for 2 hours while stirring. After cooling it is filtered, the residue washed with ethyl acetate and the filtrate evaporated in vacuo. The residue is treated with 10 ml. concentrated hydrochloric acid and extracted with ethyl acetate. The organic layer is separated, extracted with 10% aqueous potassium carbonate and the aqueous solution acidified with hydrochloric acid. The precipitate formed is filtered off, washed with water and recrystallized from aqueous ethanol to yield the 2,4-dichloro-5-(4-methyl-phenylsulfamyl)-benzoic acid melting at 202-204.

EXAMPLE According to the method shown in the previous examples the compounds of Formula I, R =furfuryl,

R2=R4:H

R =Cl, and listed below, are prepared from equivalent amounts of the corresponding starting materials of Formula II, R =X=Cl:

The mixture of 4.0 g. 2,4-dichloro-5-(4-acetylaminophenylsulfamyD-benzoic acid, 3.9 g. furfurylamiue and ml. Z-methoxy-ethanol is refluxed for 4 hours under nitrogen. After cooling it is treated with 2 N-hydrochloric acid, the residue formed separated and dissolved in 2 N- aqueous sodium hydroxide. The solution is extracted with diethyl ether, the aqueous layer separated, acidified with hydrochloric acid and the precipitate formed recrystallized from aqueous ethanol to yield the N-furfuryl-4-chloro-5- (4-acetylamino-phenylsulfamyl)anthranilic acid of the formula COOH NHCIL-H H HNO2S oH -ooNH 01 The starting material is prepared as follows: To the melting at 248 with decomposition.

solution of 5.8 g. 2,4-dichloro-5-chlorosulfonyl-benzoic acid in 50 ml. ethyl acetate, 12.0 g. 4-amino-acetanilide are added, followed by 50 ml. ethyl acetate. The mixture is stirred for 2 hours at room temperature and refluxed for 2 hours while stirring. After cooling to room temperature it is filtered, the residue (A) washed with ethyl acetate and the filtrate evaporated in vacuo. The residue (B) is triturated with water and 10 ml. concentrated hydrochloric acid, filtered oif, Washed with water and dried. The combined residues (A) and (B) are dissolved in 60 ml. 10% aqueous potassium carbonate, the solution washed with diethyl ether, acidified with hydrochloric acid, the precipitate formed filtered 0E and washed with water to yield the 2,4-dichloro-5-(4-acetylamino-phenylsulfamyl)-benzoic acid melting at about 150.

EXAMPLE 7 The mixture of 5.3 g. 2,4-dichloro-5-(4-amino-phenylsulfamyl)-benzoic acid hydrochloride, 5.4 g. furfurylamine and ml. Z-methoxy-ethanol is refluxed for 4 hours under nitrogen and evaporated in vacuo. T o the residue 30 ml. 2 N-hydrochloric acid are added and the precipitate formed filtered off. It is triturated with 40 ml. water at room temperature, filtered off, washed with a small amount of ice cold water and diethyl ether and recrystallized from aqueous ethanol to yield the N-furfuryl- 4-chloro-5-(4-amino-phenylsulfamyl)-anthranilic acid hydrochloride of the formula melting at about 230.

The starting material is prepared as follows: The mixture of 7.1 g. 2,4 dichloro 5-(4-acetylamino-phenylsulfamyl)-benzoic acid (of Eaxample 6) and ml. 2 N- aqueous sodium hydroxide is refluxed for minutes. After cooling to room temperature it is acidified with concentrated hydrochloric acid, the precipitate formed filtered oil, the residue taken up in ethanol, the solution filtered and evaporated in vacuo, to yield the 2,4-dichloro-5-(4- amino-phenylsulfamyl)-benzoic acid hydrochloride, melting at 185 with decomposition.

EXAMPLE 8 The mixture of 6.5 g. 2,4-dichloro-S-phenylsulfamylbenzoic acid, 4.6 g. (2-methyl-tetrahydrofural-Z)-methyl- 30 ml. Z-methoxy-ethanol is refluxed for 4 hours under nitrogen. After cooling to room temperature, it is poured into 180 ml. 2 N-hydrochloric acid, the precipitate separated, ground in a mortar, filtered, washed with water and recrystallized several times from aqueous ethanol to yield the N-(tetrahydrofuryl-Z-methyl)-4-chloro-5-phenylsulfamyl-anthranilic acid of the formula @-nN02s -ooon o1- Nl1--CHz-[ melting at 238-239 EXAMPLE 9 The mixture of 3.5 g. 2,4-dichloro-S-phenylsulfamylbenzoic acid, 4.6 g. (2-methyl-tetrahydrofuryl-2)-methylamine and 10 ml. 2-methoxy-ethanol is refluxed for 4 hours under nitrogen and stirred overnight at room temperature. Hereupon it is poured into 80 ml. 2 N-hydrochloric acid, the residue separated and dissolved in 2 N- aqueous sodium hydroxide. The solution is washed with diethyl ether, filtered and acidified with concentrated hydrochloricic acid. The precipitate formed is filtered off and recrystallized from aqueous ethanol, to yield the N- (2 methyl-tetrahydrofuryl-2-methyl)-4-chloro-5-phenylsulfamyl-anthranilic acid of the formula HN 02s 0 0 OH C113 j 01 NH-0H,

melting at 207-208".

EXAMPLE 10 The mixture of 6.5 g. 2-dichloro-5-phenylsulfamylbenzoic acid, 9.05 g. 2,3-dihydro-pyranyl-2-methylamine and 30 ml. 2-methoxy-ethanol is refluxed for 4 hours under nitrogen. After cooling to room temperature it is poured into 180 ml. 2 N-hydrochloric acid, the precipitate formed filtered off, washed with water and recrystallized from aqueous ethanol, to yield the N-(2,3-dihydropyranyl 2 methyl)-4-chloro-5-phenylsulfamyl-benzoic acid of the formula HN 0 is- -C 0 o H 01 NHCH2 melting at 115-117 with decomposition.

EXAMPLE 11 The mixture of 81.4 g. N-furfuryl-4-chloro-5-phenylsulfamyl-anthranilic acid (Example 1), 110 ml. 2 N aqueous sodium hydroxide and ml. water is heated to about 50 to 60 until dissolution occurs. The solution is filtered, the filtrate cooled, seeded with a few crystals of previously prepared sodium salt, and allowed to stand in the refrigerator. The precipitate formed is filtered off, washed with a small amount of ice water and dissolved in 100 ml. isopropanol at 60. The solution obtained is 1 I slowly cooled and finally kept in the refrigerator. The precipitate formed is filtered oif, triturated with 75 ml. cold isopropanol, filtered again and dried to yield the sodium salt of the N-furfuryl-4-chloro-5-phenylsulfamylanthranilic acid, melting at 244 to 246 with decomposition.

EXAMPLE 12 The mixture of 2.0 g. N-benzyl-4-chloro-5-phenyl-sulfamyl-anthranilic acid, 2 ml. acetic acid anhydride and 8 ml. pyridine is heated at the steam bath for 1 hour, cooled and poured into water. The mixture is slightly acidified with concentrated hydrochloric acid, the precipitate formed filtered oif and dissolved in ethanol. To the solution, water and a few drops hydrochloric acid are added, the precipitate formed filtered 011? and again recrystallized from aqueous ethanol to yield the N,N'-bisacetyl-N- benzyl-4-chloro-5-phenylsulfamyl-anthranilic acid of the formula CH -C\ N0 8 COOH (I l I 2 o (PO-CH3 melting at 206-208 EXAMPLE 13 The mixture of 113.3 g. 2,4-dichloro-S-phenylsulfamylbenzoic acid, 500 ml. Z-methoxy-ethanol and 126.0 g. furfurylamine is stirred and refluxed under nitrogen for t hours. The cold mixture is then slowly poured into 2.5 liters 2 N hydrochloric acid while stirring. The precipitate formed is filtered off, washed with water and dissolved in 1 liter 2 N aqueous sodium hydroxide. The dark solution obtained is extracted three times with 125 ml. methylene chloride each and the aqueous layer carefully acidified with concentrated hydrochloric acid. The precipitate formed is filtered off, dissolved in 1 liter ethanol, the solution decolorized with charcoal, filtered hot, the filtrate combined with 1 liter hot water and, upon cooling to 15, the N-furfuryl-4-chloro-5-phenylsulfamyl-anthranilic acid (Example 1) crystallizes. It is filtered OE and dried; it melts at about 206, which melting point can be raised to 208210 by another recrystallization.

The starting material is prepared as follows: The mixture of 150 g. 2,4-dichloro-benzoic acid and 600 g. chlorosulfonic acid is heated to 150-155 for 3 hours while stirring. Thereupon, 223 g. chlorosulfonic acid are distilled off in vacuo and the cold residue poured into a mixture of 1.65 kg. ice and 125 water. The precipitate formed is filtered oif, washed with cold water, dissolved in 800 ml. ethyl acetate, the solution dried, filtered, and the filtrate diluted with 600 ml. ethyl acetate. To the solution obtained (containing the 2,4-dichloro--chlorosulfonyl-benzoic acid), cooled in a water bath, the mixture of 216 g. aniline and 220 ml. ethyl acetate is added at such rate that the temperature stays below 30. The mixture is stirred for 4 hours at 25-30", whereupon 4 g. charcoal are added. It is then filtered, the residue washed with 125 ml. ethyl acetate, the filtrate washed first with 450 ml. 3 N hydrochloric acid, then with 550 ml. Water, and finally extracted with 700 ml. 7% aqueous sodium carbonate. The aqueous extract is separated, carefully acidified with concentrated hydrochloric acid and the precipitate formed filtered otf and dried at 75 in vacuo, to yield the 2,4-dichloro-5phenylsulfamylbenzoic acid melting at 212-216.

EXAMPLE 14 The mixture of equivalent amounts of 2,4-dichloro-5- (2,3-dihydro 6 thianaphthylsulfamyl)-benzoic acid and 0.5 ml. benzylamine in 1 ml. Z-methoxy-ethanol is heated for 4 hours to 130. After cooling, 5 ml. 2 N hydrochloric acid and 5 ml. water are added, the precipitate formed 12 filtered off, washed with water and triturated with 2 N aqueous sodium hydroxide. The alkaline solution is filtered, the filtrate acidified with hydrochloric acid, the precipitate formed filtered off, washed with water and dried, to yield the N-benzyl-4-chloro-5-(2.,3-dihydro-6- thianaphthylsulfamyl)-anthranilic acid of the formula melting at 150 with decomposition.

The starting material is prepared as follows: To the solution of 1.9 g. 6-amino-2,3-dihydro-thianaphthene in 25 ml. ethyl acetate and 3 ml. pyridine, 2.9 g. 2,4-dichloro-5-chlorosulfonyl-benzoic acid are added slowly While stirring. The mixture is stirred for 3 hours at room temperature and allowed to stand overnight. It is made strongly acidic 'with hydrochloric acid, extracted with ethyl acetate, the extract washed with water, dried and evaporated in vacuo. The residue is taken up in 1 N aqueous sodium hydroxide, the solution filtered and the filtrate acidified. The precipitate formed is filtered 01f and recrystallized first from aqueous ethanol and finally from methanol, to yield the 2,4-dichloro-5-(2,3dihydro-6-thianaphthylsulfarnyl) -benzoic acid.

EXAMPLE 15 The mixture of 3.6. g. 2,4-dichloro 5 (N-methyl-N- phenylsulfamyl)-benzoic acid, 3.9 g. furfurylamiue and 10 ml. Z-methoxyethanol is refluxed for 4 hours under nitrogen. After cooling, it is poured into 50 ml. 2 N hydrochloric acid, the precipitate formed filtered off, washed with water and heated with 50 ml. 2 N aqueous sodium hydroxide. To the suspension obtained, water and diethyl ether are added until 2 clear layers are formed. The aqueous layer is separated, washed with diethyl ether and acidified with hydrochloric acid. The precipitate formed is filtered off and recrystallized from aqueous ethanol, to yield the N- furfuryl-4-chloro-S-(N-methyl-N-phenylsulfa-myl)-anthranilic acid of the formula 1 i ll 0 01 i Nil-CH o melting at 171472".

In the analogous manner, the N-benzyl-4-chloro-5- (N- methyl N phenylsulfamyl)-anthranilic acid is obtained; Md. 164-166.

The starting material is prepared as follows: To the solution of 11.6 g. 2,4dichloro-5-chlorosulfonyl-benzoic acid in ml. ethyl acetate, 17.1 g. N-methyl-aniline are added slowly, and the mixture is stirred at room temperature for 4 hours. It is then filtered, the filtrate evaporated in vacuo and the residue taken up in water and 20 ml. concentrated hydrochloric acid. The mixture is extracted with ethyl acetate, the extract washed with water and shaken with 10% aqueous potassium carbonate. The aqueous layer is separated, acidified with concentrated hydrochloric acid, the precipitate for-med filtered off and recrystallized from aqueous ethanol to yield the 2,4-dichloro-S-(N-methyl-N-phenylsulfamyl)-benzoic acid, melting at 170l71.

EXAMPLE 16 The mixture of 3 g. N-benzyl-4-chloro-5-(N-methyl-N- phenylsulfamyl)-anthranilic acid (Example 15), 12 ml. pyridine and 3 ml. acetic acid anhydride is heated at the steam bath for 1 hour while stirring. After cooling, it is poured into ml. water, the mixture acidified with concentrated hydrochloric acid, the precipitate collected and recrystallized from aqueous methanol to yield the N-acetyl-N-benzyl-4-chloro-5-(N-methyl N phenylsulfamy=l)-anthranilic acid of the formula.

I NOzS COOH N-CH2 CO-CH3 melting at 176-177 with decomposition.

EXAMPLE 17 The mixture of equivalent amounts of 2,4-dichloro-- phenylsulfamyl-benzoic acid and 9.7 g. N-methyl-benzylamine in 20 ml. 2-methoxy-ethano1 is refluxed for 4 hours under nitrogen. After cooling, it is poured into 100 ml. 2 N-hydrochloric acid, the precipitate formed filtered off, washed with water and dissolved in 2 N aqueous sodium hydroxide. The mixture is extracted with diethyl ether, the aqueous layer separated and acidified with concentrated hydrochloric acid. The precipitate formed is filtered off and recrystallized from aqueous ethanol, to yield the N-methyl-N-benzyl 4 chloro 5 phenylsulfamylanthranilic acid of the formula HNOQS 00011 Cl -CH melting at 183-l84 with decomposition.

EXAMPLE 18 The mixture of 3 g. N-methyl-N-benzyl-4-ch1oro-5- phenylsulfamyl-anthranilic acid (Example 17), 12 ml. pyridine and 3 ml. acetic acid anhydride is heated at the steam bath for 1 hour while stirring. After cooling, it is poured into 120 ml. water, the mixture acidified with concentrated hydrochloric acid and the precipitate formed filtered off. The residue is dissolved in the minimum amount of hot ethanol, the solution filtered and allowed to cool to room temperature. The precipitate formed is filtered off and washed with aqueous ethanol to yield the N-methyl-N-benzyl 4 chloro 5 (N-acetyl-N-phenylsulfamyl)-anthranilic acid of the formula on -co 3 no s coon o :rr,.o

melting at l9l-192 with decomposition.

EXAMPLE 19 Preparation of 10,000 tablets each containing 50.0 mg. of the active ingredient:

Purified water, q.s.

Procedure All the powders are passed through a screen with an opening of 0.6 mm. Then the drug substance, lactose, talcum, magnesium stearate and half of the starch are mixed in a suitable mixer. The other half of the starch is suspended in 45 ml. water and the suspension added to the boiling solution of the polyethylene glycol in 180 14 ml. water. The paste formed is added to the powders which are granulated, if necessary, with an additional amount of water. The granulate is dried overnight at 35", broken on a screen with 1.2 mm. openings and compressed into tablets using concave punches with 7.1 mm. diameter, uppers bisected.

EXAMPLE 20 The mixture of 2.2 g. methyl 4 chloro-S-phenylsulfamyl-anthranilate and 12 ml. benzaldehyde is heated to 200 for 1 hour and evaporated in vacuo. The residue is triturated with ml. ethylacetate, filtered 0E and the filtrate hydrogenated over 0.3 g. platinum dioxide at room temperature until the hydrogen uptake slows down /2 an hour). The mixture is filtered, the filtrate evaporated in vacuo, the residue taken up in chloroform-diethylamine (921) and chromatographed on silica gel, to yield as the main eluate the amorphous methyl N-benzyl-4- chloro-5-phenylsulfamyl-anthranilate of the formula HNOQS 000011 showing in the I.R.-spectrum bands, inter alia at 1750 and 1250 CHI-T1.

1.8 g. thereof are dissolved in 20 ml. methanol and 10 ml. 2 N aqueous sodium hydroxide, and the solution is refluxed for 20 minutes. It is then concentrated in vacuo, the aqueous concentrate diluted with water, extracted with diethyl ether and the aqueous layer acidified with hydrochloric acid. The precipitate formed is filtered 01f and recrystallized from aqueous ethanol, to yield the N-benzyl 4 chloro 5 phenylsulfamyl-anthranilic acid melting at 226-228"; it is identical with the product obtained according to Example 3.

The starting material is prepared as follows: The mixture of 1.0 g. 2,4-dichloro-S-phenylsulfamyl-benzoic acid and 25 ml. concentrated aqueous ammonia is heated in a sealed tube to for 4 hours. Hereupon, it is evaporated in vacuo, the residue taken up in 25 ml. saturated anhydrous methanolic hydrochloric acid and the mixture gently refluxed for 1 hour. It is evaporated in' vacuo and the residue recrystallized from methanol, to yield the methyl 4-chloro-5-phenylsulfamyl-anthranilate melting at 183-186.

EXAMPLE 21 The mixture of 2.0 g. methyl 4-chloro-5-phenylsulfamylanthranilate and 5 ml. benzyl chloride is refluxed for 2 hours and evaporated in vacuo. The residue is triturated with diethyl ether, filtered off and washed with diethyl ether to yield the methyl N-benzyl-4-chloro-5-phenylsul famyl-anthranilate melting at about 200 (softening at 185); it is identical with the compound obtained according to Example 20.

The mixture of 1.3 g. thereof, 5 ml. methanol, 5 ml. water and 1.5 ml. 6 N aqueous sodium hydroxide is heated at the steam cone for 30 minutes and allowed to stand at 25 for 1 hour. It is then concentrated in vacuo, the concentrate diluted with water, extracted with diethyl ether and the aqueous layer filtered. The filtrate is acidified with hydrochloric acid to pH 5, the precipitate formed filtered off and recrystallized from aqueous ethanol, to yield the N-benzyl-4-chloro-S-phenylsulfamylanthranilic acid melting at 226; it is identical with the product obtained according to Example 3.

EXAMPLE 22 To the suspension of 4.07 g. N-furfuryl-5-phenylsulfamyl-4-chloro-anthranilic acid and 50 ml. methanol, 0.61 g. 2-hydroxyethylamine are added while stirring. The resulting yellowish solution is evaporated in vacuo, to yield the 2-hydroxyethyl-ammonium N-furfuryl 5 phenylsulfamyl-4-chloro-anthranilate of the formula 'HNO S COONH CH Cll OH U (1U NH- CH l I 2 melting at 90 EXAMPLE 23 The mixture of 13.1 g. ethyl 2,4-dichloro--phenylsulfarnyl-benzoate and 20.4 g. furfurylamine is heated for 1 hour to 110. After cooling, it is poured into 210 ml. water, the mixture acidified with glacial acetic acid to pH 4.5 while keeping the temperature below 20. The precipitated formed is filtered off, washed with water and suspended in 250 ml. 0.5 N sodium hydroxide while stirring at room temperature. It is filtered, the residue suspended in water and the mixture acidified with hydrochloric acid to pH 2 while stirring. It is again filtered and the residue recrystallized several times from aqueous ethanol and finally from anhydrous ethanol, to yield the ethyl N-furfuryl-5-sulfamyl-4-chloroanthranilate of the formula HNOZS C00C l-l c (unmi- CH i i 2 o melting at 157-159".

The starting material is prepared as follows: The mixture of 15 g. 2,4-dichloro-S-phenylsulfamyl-benzoic acid and 150 ml. 6 N ethanolic hydrochloric acid is refluxed for 90 minutes and allowed to stand in the cold. The precipitate formed is filtered otf, and recrystallized from aqueous ethanol, to yield the ethyl 2,4-dichloro-5-phenylsulfamyl-benzoate melting at l32l33.

EXAMPLE 24 The mixture of 6.6 g. 2,4-dichloro-5-phenylsulfamylbenzoic acid 3-dimethylarnino-propylamide, 5.8 g. furfurylamine and 15 ml. 2-methoxy-ethanol is refluxed for 4 hours under nitrogen and evaporated in vacuo. The residue is taken up in 100 ml. 2 N aqueous sodium hydroxide and the mixture extracted with ethyl acetate. The organic layer is dried, filtered and evaporated. The residue is triturated with hydrogen chloride in ethyl acetate, the precipitate formed filtered ofi and taken up in water. The solution is washed with ethyl acetate, filtered and made basic with 2 N aqueous sodium hydroxide. The mixture is extracted with ethyl acetate, the extract dried, filtered and evaporated, to yield the amorphous N-furfuryl-S- phenylsulfamyll-chloro-anthranilic acid S-dimethylaminopropylamide of the formula chloroform, methanol and diethylamine (8515110) an The starting material is prepared as follows: To the mixture of 17.7 g. 2,4-dichloro-5-phenylsulfamyl-benzoic acid and 90 ml. 1,2-dimethoxyethane, 24 ml. thionyl chloride are added dropwise during 25 minutes While stirring, the whole is refluxed for 90 minutes and evaporated in vacuo. 18.6 g. of the resulting acid chloride is taken up in 300 ml. ethyl acetate and the solution added dropwise to the mixture of 11.8 g. 3-dimethylaminopropylamine and. 450 ml. ethyl acetate while stirring, and stirring is continued overnight at room temperature. The mixture is filtered, the filtrate acidified with hydrogen chloride in ethyl acetate and the precipitate formed filtered off. It is taken up in water, the solution washed with ethyl acetate and made alkaline with potassium carbonate. The mixture is extracted with ethyl acetate, the mixture dried,

1 6 filtered and evaporated, to yield the 2,4-dichloro-5-phenyL sulfamyl-benzoic acid 3-dimethylamino-propylamide melting between about and EXAMPLE 25 The mixture of 3.6 g. 2,4-dichloro-5-(4-hydroxyphenylsulfamy1)-benzoic acid, 10 ml. Z-methoxy-ethanol and 3.9 g. furfurylamine is refluxed for 4 hours under nltrogen. After cooling, it is poured into 50 ml. 2 N hydrochloric acid, the precipitate formed filtered ofi, washed with water and taken up in 2 N aqueous sodium hydroxide. The mixture is washed with diethyl ether, filtered and the filtrate acidified with concentrated hydrochloric acid. The precipitate formed is filtered off and recrystallized from aqueous ethanol, to yield the N-furfuryllchloro-S-(4-hydroxyphenylsulfamyl)-anthranilic acid of the formula HN02 S coon HO/ 3 01min:- cn i 'i melting at 227 with decomposition.

The starting material is prepared as follows: To the mixture of 5.8 g., 2,4-dichloro-5-chlorosulfonyl-benzoic acid and ml. ethyl acetate, 8.7 g. 4-hydroxyaniline are added portionwise and the mixture stirred at room temperature for 4 hours. After standing overnight, it is filtered, the residue suspended in 50 ml. water, the mixture acidified with 10 ml. concentrated hydrochloric acid and extracted with ethyl acetate. The extract is filtered, washed with Water and shaken with 10% aqueous potassium carbonate. The aqueous solution is filtered, acidified with concentrated hydrochloric acid and the precipitate formed filtered Off. It is recrystallized several times from aqueous ethanol, to yield the 2,4-dichloro-5-(4-hydroxyphenylsulfamyD- benzoic acid melting at 233-235.

EXAMPLE 26 In the manner described in Example 25, the N-furfuryl- 4-chloro-5-(2-hydroxyphenyl-sulfamyl) anthranilic acid, MP. (dec.) and the N-furfuryl-4-chloro-5-(3-hy droxyphenylsulfamyl)-anthranilic acid, M.P. 202 (dec.) are prepared from the same amounts of the corresponding isomeric starting materials, which melt at 187-189 and 192-194 respectively.

EXAMPLE 27 The mixture of 3.9 g. 2,4-dicholro-5-(3,4-dimethoxypheuyl-sulfamyD-benzoic acid, 10 m1. Z-methoxyethanol and 3.7 g. furfurylamine is refluxed for 4 hours under nitrogen. After cooling, it is poured into 50 ml. 2 N hydrochlorie acid, the precipitate formed filtered off, washed with water and taken up in 2 N aqueous sodium hydroxide. The mixture is washed with diethyl ether, filtered, the filtrate acidified with concentrated hydrochloric acid, the precipitate formed collected and recrystallized two times from aqueous ethanol, to yield the N-furfuryl-4- chloro-S-(3,4-dimethoxyphenyl-sulfamyl)-anthranilic acid of the formula arated, extracted with 10% aqueous potassium carbonate and the extract acidified with concentrated hydrochloric 1 7 acid. The precipiate formed is filtered oil and recrystallized two times from aqeuous ethanol, to yield the 2,4-dichloro--(3,4-dimethoxyphenyl-sulfamyl) benzoic acid melting at 202203.

EXAMPLE 28 In the manner described in Example 27, the N-furfuryl- 4-chloro-5-(2,4 dimethoxyphenylsulfamyl) anthranilic acid, M.P. 103 and the N-furfuryl-4-chloro-5-(2,5 dimethoxyphenylsulfamyl)-anthranilic acid, M.P. 199-202 are prepared from the same amounts of the corresponding isomeric starting materials, which melt at 184-185 and 180-182 respectively.

EXAMPLE 29 Preparation of 1,000 capsules, each containing 25 mg. of the active ingredient:

Formula G. N-furfuryl-4-chloro-5-(4-hydroxyphenylsulfamyl)- anthranilic acid 25.0

Lactose i I 220.0

Procedure The ingredients are intimately mixed in a suitable mixer, passed through a screen with openings of 0.6 mm., re-mixed and 245 mg. are filled into No. 3 hard shell gelatin capsules.

In the analogous manner, capsules are prepared containing per unit 75 mg. N-furfuryl-4-chloro-5-(4-methoxyphenylsulfamyl)-anthranilic acid or N-furfuryl-4- chloro-S-(4-aminophenylsulfamyl)-anthranilic acid hydrochloride and 170 mg. lactose.

EXAMPLE 31 Preparation of 10,000 tablets, each containing 50 mg. of the active ingredient:

Formula N-furfuryl-4-ch10ro-i-phenyl-sulfamyl-anthranilic acid 500.0 Lactose 2,500.0 Microcrystalline cellulose 1,000.0 Corn starch 160.0 Magnesium stearate 40.0

Purified water, q.s.

Procedure All the powders, except the starch and the magnesium stearate, are passed through a screen with 0.6 mm. openings and mixed in a suitable mixer. The starch is suspended in 160 ml. water and the suspension added to 200 ml. boiling water. The paste formed is added to the powders which are granulated, if necessary, with an additional amount of water. The granulate is dried overnight at 35, broken on a screen with 1.2 mm. openings, the magnesium stearate added, mixed well and the granulate compressed into 420 mg. tablets using concave punches with 7.1 mm. diameter, uppers bisected.

18 What is claimed is: 1. The pharmaceutical composition comprising essentially a diuretically effective amount of a compound having the formula in which each of R, and R is phenyl, monoor di-lower alkylphenyl lower hydroxyalkylphenyl, mono or dihydroxyphenyl, lower alkyl-hydroxyphenyl, monoor di-mercaptophenyl, monoor di-lower alkoxyphenyl, lower alkoxy-hydroxyphenyl, hydroxy-lower alkoxyphenyl, monoor di-lower alkylmercaptophenyl, monoor dihalogenophenyl, trifluoromethylphenyl, nitrophenyl, monoor diaminophenyl, di-lower alkylaminophenyl, lower alkanoylaminophenyl, carboxyphenyl, carbo-lower alkoxyphenyl, pyridyl, lower alkylpyridyl, furyl, lower alkylfuryl, thienyl, lower alkylthienyl, tetrahydrofuryl, lower alkyltetrahydrofuryl, dihydropyranyl or lower alkyldihydropyranyl, and each of R and R is hydrogen or lower alkanoyl; or a lower alkyl ester thereof, the amide, a monoor diloweralkylamide thereof, a (hydroxy or lower alkoxy)- lower alkyl ester or amide, (amino, monoor di-lower alkylamino)-lower alkyl ester or amide thereof, in which esters or amides the hydroxy, alkoxy or amino groups are separated from the carboxy oxygen or carbamoyl nitrogen by at least 2 carbon atoms, and lower defines said radicals such with up to 4 carbon atoms, or the alkali metal, alkaline earth metal or ammonium salts of said anthranilic acids or therapeutically useful acid addition salts of basic compounds, together with an enterally or parenterally applicable excipient.

2. The composition of claim 1, wherein the diuretically eifective compound is that of the formula wherein R is phenyl, Z-furyl, 2-thienyl, Z-tetrahydrofuryl, 2-methyl-Z-tetrahydrofuryl or 2,3-dihydro-2-pyranyl, each of R and R is hydrogen or acetyl and R is phenyl, monoor dimethylphenyl, Z-hydroxyethylphenyl, monoor dihydroxyphenyl, methyl-hydroxyphenyl, mercaptophenyl, monoor dimethoxyphenyl, methoxy-hydroxyphenyl, 2-hydroxyethoxyphenyl, fiuorophenyl, chlorophenyl, trifluoromethylphenyl, nitrophenyl, monoor diaminophenyl, dimethylaminophenyl, acetylaminophenyl, carboxyphenyl, carbomethoxyphenyl or carbethoxyphenyl, or the methyl or ethyl ester, the 3-dimethylaminopropyl amide, the sodium, potassium or 2-hydroxyethylammonium salts of the carboxylic acids or the hydrochlorides of the monoor diamino or dimethylamino compounds.

3. A composition as claimed in claim 1, wherein the diuretically effective compound is the N-furfuryl-4-chloro- S-(aminophenylsulfamyl)-anthranilic acid, the sodium, potassium, Z-ethanolammonium salt or the hydrochloride thereof.

References Cited UNITED STATES PATENTS 3,009,910 11/1961 Ziegler 260239.6 3,072,656 1/ 1963 Werner et al. 260397.7

OTHER REFERENCES Yale, J.Med. Chem, vol. 1, pp. 121-33 (1959).

ALBERT T. MEYERS, Primary Examiner F. E. WADDELL, Assistant Examiner US. Cl. X.R. 

